Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Doubles Down On Orthopedics With Synthes Deal; Takes Lead In Trauma

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson will control a majority of the orthopedic trauma device market and double its stake in the spinal device field by acquiring Synthes for $21.3 billion under a definitive agreement announced April 27.

You may also be interested in...



Actelion Could Succumb To Big Pharma's Charms

News that Europe’s largest biotech Actelion is in preliminary discussions with Johnson & Johnson about a transaction has been viewed favourably by investors, and could see the return of mega-merger activity to other big pharma companies.

New Ortho Juggernaut: Zimmer Acquires Biomet For $13.35 Billion

Zimmer has agreed to buy Biomet by the first quarter of 2015, furthering the trend of consolidation in the $45 billion orthopedic device industry. The companies had combined revenues of $7.8 billion in 2013.

Charting Emerging Markets: J&J Growth Rates

PharmAsia News takes a closer look at J&J’s growth in key emerging markets.

Related Content

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel